Top Story

Spark Therapeutics reports $16.9 million net loss in third quarter

November 25, 2015

Spark Therapeutics reported a net loss of $16.9 million, or $0.70 per basic and diluted share, in the third quarter compared with a net loss of $6.8 million, or $1.22 per basic and diluted share, in the same quarter of 2014, according to a press release.

Revenue was reported at $1.3 million in the third quarter compared with no revenue reported in the same quarter of 2014. The increase was attributed to a collaboration with Pfizer.

Meeting News CoverageVideo

VIDEO: Surgeon's experience — Toric lenses improve astigmatism correction

November 25, 2015
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Rex Hamilton, MD, MS, FACS, discusses how the availability of Tecnis toric lenses (Abbott Medical…
Meeting News Coverage

No change seen in binocular contrast sensitivity after inlay procedure

November 24, 2015
NEW ORLEANS – A mild decrease in monocular contrast sensitivity was seen after Kamra inlay implantation, but binocular contrast sensitivity “remained…

ACOE grants new Kentucky optometry school preliminary approval

November 24, 2015
The University of Pikeville-Kentucky College of Optometry announced that the Accreditation Council on Optometric Education granted the college the pre-accreditation…
Meeting News Coverage

AAO launches effort to rebrand itself as vanguard of eye care

November 24, 2015
The American Academy of Ophthalmology is embarking on an initiative to rebrand itself and foster an understanding of the specialty’s impact on society, a speaker…
More News Headlines »
Meeting News Coverage

Improvements in visual acuity with corneal inlay remain stable long-term

November 16, 2015
NEW ORLEANS – A study involving 253 subjects who received the Kamra corneal inlay in their nondominant eye showed…
More »

Arizona allows sale of adjustable focus eye wear without prescription

October 29, 2015
Arizona now permits the sale of adjustable eye wear without a prescription, based on a ruling by the assistant attorney…
More »

Allergan seeks approval for preservative-free Restasis

November 13, 2015
Allergan announced it has submitted a Prior Approval Supplement for Restasis 0.05% to obtain marketing clearance for a…
More »
Current Issues
View the Current Issue
Primary Care Optometry News
morganatic-roan morganatic-roan